Observational studyDiabetes, obesity & metabolism2026
Real-world evaluation of clinical outcomes in Dutch patients with type 2 diabetes treated with oral semaglutide: A retrospective, observational cohort study using the PHARMO data network.
Observational study in Diabetes, obesity & metabolism, 2026. The graph read 2 numbers from its abstract, feeding 2 cells of the map, but none could be read as for or against, so it casts no vote. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
Read, but not usablea number the graph found but could not read as for or against
Body weight was reduced by -4.73 (-3.63, -5.83) kg at 12 months in 260 patients over an average of 8.2 months follow-up.
In 320 patients with an average follow-up of 8.1 months the mean (95% confidence interval) change in HbA1c from baseline was -16.05 (-12.57, -19.54) mmol/mol at 12 months, of whom 70% achieved personalized HbA1c targets.
clause the extractor read what became the number
Where it lands on the map
Rows are treatments, columns are outcomes. The coloured squares are the cells this paper feeds, coloured by the vote it casts there. Click one to jump to what this paper adds to it.
What it adds to each cell
For every cell the paper feeds: the belief in the claim with and without this paper, and this paper's estimate drawn against every other readable study in the cell. The ringed dot is this paper.
GLP-1 receptor agonists×body weight & composition
No readable resultOpen on the map →What to test next →40 readable studies in this cell: 74 favour the treatment, 15 find no difference, 10 favour the comparator.
This paper's own estimate is on a different scale from the rest of the cell, so it is not drawn here.
GLP-1 receptor agonists×glycemic control
No readable resultOpen on the map →What to test next →40 readable studies in this cell: 89 favour the treatment, 16 find no difference, 10 favour the comparator.
This paper's own estimate is on a different scale from the rest of the cell, so it is not drawn here.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nationwide Real-World Retrospective Study of Oral Semaglutide Use in Adults Living With Type 2 Diabetes in Finland.Diabetes, obesity & metabolism · 2026Article
- Real-world evaluation of clinical outcomes in Dutch patients with type 2 diabetes treated with oral semaglutide: A retrospective, observational cohort study using the PHARMO data network.Diabetes, obesity & metabolism · 2026 · on this mapObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The marked sentences are the ones the graph read a number from.
aimA retrospective observational cohort study, in the Netherlands, evaluated clinical outcomes with oral semaglutide.
methodsGlucagon-like peptide-1 receptor agonists (GLP-1ra) naïve type 2 diabetes (T2D) patients who initiated oral semaglutide between 1 January 2020 and 31 December 2022 were identified from the PHARMO Data Network. Change from baseline was evaluated in glycated haemoglobin (HbA1c), body weight, blood lipids, and blood pressure over 12 months of follow-up. Outcomes were analysed in patients with at least a baseline and ≥1 follow-up measurement, using mixed-effect models for repeated measurements.
resultsOf 932 T2D patients initiating oral semaglutide identified, 731 were GLP-1ra naïve (mean [standard deviation] age, 62 [11] years; baseline HbA1c, 70 [14] mmol/mol; baseline body weight, 102 [19] kg). In 320 patients with an average follow-up of 8.1 months the mean (95% confidence interval) change in HbA1c from baseline was -16.05 (-12.57, -19.54) mmol/mol at 12 months, of whom 70% achieved personalized HbA1c targets. Body weight was reduced by -4.73 (-3.63, -5.83) kg at 12 months in 260 patients over an average of 8.2 months follow-up. Minimal changes were observed in blood lipid parameters and diastolic blood pressure, with moderate changes in systolic blood pressure.
conclusionsAmong Dutch T2D patients who were GLP-1ra naïve and initiated oral semaglutide, significant reductions in HbA1c and body weight were observed over 12 months, consistent with prospective clinical trial data. These results provide a first-look insight into real-world glycaemic control and body weight reduction in early adopters of oral semaglutide in the Netherlands.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.